Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.
about
Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.Radiotherapy and Glioma Stem Cells: Searching for Chinks in Cellular Armor.Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin.Inhibition of cell-adhesion protein DPYSL3 promotes metastasis of lung cancer.
P2860
Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Radiation Resistance in KRAS-M ...... y an Osteopontin-EGFR Pathway.
@en
Radiation Resistance in KRAS-M ...... y an Osteopontin-EGFR Pathway.
@nl
type
label
Radiation Resistance in KRAS-M ...... y an Osteopontin-EGFR Pathway.
@en
Radiation Resistance in KRAS-M ...... y an Osteopontin-EGFR Pathway.
@nl
prefLabel
Radiation Resistance in KRAS-M ...... y an Osteopontin-EGFR Pathway.
@en
Radiation Resistance in KRAS-M ...... y an Osteopontin-EGFR Pathway.
@nl
P2093
P2860
P1433
P1476
Radiation Resistance in KRAS-M ...... y an Osteopontin-EGFR Pathway.
@en
P2093
Cyril H Benes
Henning Willers
Jing X Kang
Johnathan R Whetstine
Josh Black
Kristin Gurtner
Kshithija Nagulapalli
Lecia V Sequist
Lynnette Marcar
P2860
P304
P356
10.1158/0008-5472.CAN-16-0808
P407
P577
2017-02-15T00:00:00Z